Advertisement

Janus kinase inhibitors in patients with ankylosing spondylitis: Great news, but some concerns on cardiovascular disease risk still exist. Author's reply

      We appreciate the opportunity to reply to the Letter to the Editor by Dimosiari and colleagues [
      • Dimosiari A.
      • Michailidis T.
      • Patoulias D.
      Janus kinase inhibitors in patients with ankylosing spondylitis: great news, but some concerns on cardiovascular disease risk still exist.
      ], commenting on our work [
      • Li S.
      • Li F.
      • Mao N.
      • Wang J.
      • Xie X.
      Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis.
      ]. We concur with them that the cardiovascular disease (CVD) risk of Janus kinase (JAK) inhibitors in patients with ankylosing spondylitis (AS) deserves attention.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dimosiari A.
        • Michailidis T.
        • Patoulias D.
        Janus kinase inhibitors in patients with ankylosing spondylitis: great news, but some concerns on cardiovascular disease risk still exist.
        Eur J Intern Med. 2022; https://doi.org/10.1016/j.ejim.2022.05.033
        • Li S.
        • Li F.
        • Mao N.
        • Wang J.
        • Xie X.
        Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis.
        Eur J Intern Med. 2022; https://doi.org/10.1016/j.ejim.2022.04.007
        • Castaneda S.
        • Vicente-Rabaneda E.F.
        • Garcia-Castaneda N.
        • Prieto-Pena D.
        • Dessein P.H.
        • Gonzalez-Gay M.A.
        Unmet needs in the management of cardiovascular risk in inflammatory joint diseases.
        Expert Rev Clin Immunol. 2020; 16: 23-36https://doi.org/10.1080/1744666X.2019.1699058
        • Lai Y.F.
        • Lin T.Y.
        • Chien W.C.
        • Sun C.A.
        • Chung C.H.
        • Chen Y.H.
        • et al.
        Uveitis as a risk factor for developing acute myocardial infarction in ankylosing spondylitis: a national population-based longitudinal cohort study.
        Front Immunol. 2021; 12811664https://doi.org/10.3389/fimmu.2021.811664
        • Arida A.
        • Protogerou A.D.
        • Kitas G.D.
        • Sfikakis P.P.
        Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases.
        Int J Mol Sci. 2018; 19: 1890https://doi.org/10.3390/ijms19071890
        • Toussirot E.
        The risk of cardiovascular diseases in axial spondyloarthritis.
        Curr Insights Front Med (Lausanne). 2021; 8782150https://doi.org/10.3389/fmed.2021.782150
        • Navarini L.
        • Currado D.
        • Marino A.
        • Di Donato S.
        • Biaggi A.
        • Caso F.
        • et al.
        Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis.
        Sci Rep. 2022; 12: 7498https://doi.org/10.1038/s41598-022-11640-8
        • Atzeni F.
        • Popa C.D.
        • Nucera V.
        • Nurmohamed M.T.
        Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.
        Expert Rev Clin Immunol. 2022; 18: 233-244https://doi.org/10.1080/1744666X.2022.2039630
        • Yang Y.
        • Li X.F.
        • Zhang X.
        • Bao C.D.
        • Hu J.K.
        • Xu J.H.
        • et al.
        Efficacy and safety of baricitinib in chinese rheumatoid arthritis patients and the subgroup analyses: results from study RA-BALANCE.
        Rheumatol Ther. 2020; 7: 851-866https://doi.org/10.1007/s40744-020-00231-6
        • Perez-Baos S.
        • Barrasa J.I.
        • Gratal P.
        • Larranaga-Vera A.
        • Prieto-Potin I.
        • Herrero-Beaumont G.
        • et al.
        Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis.
        Br J Pharmacol. 2017; 174: 3018-3031https://doi.org/10.1111/bph.13932
        • Charles-Schoeman C.
        • Fleischmann R.
        • Davignon J.
        • Schwartz H.
        • Turner S.M.
        • Beysen C.
        • et al.
        Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.
        Arthritis Rheumatol. 2015; 67: 616-625https://doi.org/10.1002/art.38974
        • Ashmawy A.I.
        • El-Abhar H.S.
        • Abdallah D.M.
        • Ali M.A.
        Chloroquine modulates the sulforaphane anti-obesity mechanisms in a high-fat diet model: role of JAK-2/STAT-3/ SOCS-3 pathway.
        Eur J Pharmacol. 2022; 927175066https://doi.org/10.1016/j.ejphar.2022.175066
        • Ungprasert P.
        • Srivali N.
        • Kittanamongkolchai W.
        Ankylosing spondylitis and risk of venous thromboembolism: a systematic review and meta-analysis.
        Lung India. 2016; 33: 642-645https://doi.org/10.4103/0970-2113.192862
        • Lu W.J.
        • Lin K.C.
        • Huang S.Y.
        • Thomas P.A.
        • Wu Y.H.
        • Wu H.C.
        • et al.
        Role of a Janus kinase 2-dependent signaling pathway in platelet activation.
        Thromb Res. 2014; 133: 1088-1096https://doi.org/10.1016/j.thromres.2014.03.042
        • Yates M.
        • Mootoo A.
        • Adas M.
        • Bechman K.
        • Rampes S.
        • Patel V.
        • et al.
        Venous thromboembolism risk with JAK inhibitors: a meta-analysis.
        Arthritis Rheumatol. 2021; 73: 779-788https://doi.org/10.1002/art.41580